Dr. Reddy's Laboratories announces launch of Bivalirudin for Injection in the U.S. Market
Dr. Reddy’s Laboratories has launched Bivalirudin for Injection, 250 mg/vial, a therapeutic equivalent generic version of Angiomax (Bivalirudin) for Injection, approved by the U.S. Food and Drug Administration (USFDA).
The Angiomax brand and generic had US sales of approximately $198 million MAT for the most recent twelve months ending in March 2017 according to IMS Health. Dr. Reddy’s Bivalirudin Injection, 250 mg/vial, are available in packages of 10 single-dose vials. Angiomax is a registered trademark of The Medicines Company.